732 results about "Tumor targeting" patented technology

The invention relates to the technical field of tumor treatment, in particular to an intelligent decision-making system for tumor precise targeted medication based on individual mutation information, which comprises a data processing layer, a variation annotation and function prediction layer, a knowledge base integration layer and a scheme decision-making engine and report visualization module. According to the intelligent decision-making system for tumor precise targeted medication based on individual mutation information, a rule engine and a prediction model are combined, dynamic priority ranking is output, multi-model fusion decision making is achieved, and clinical scene deep adaptation is achieved by predicting primary and secondary drug resistance, calculating liver and kidney function adjusting dosage and generating a combined medication time sequence scheme; through an individualized drug delivery scheme, combination drug use optimization is achieved, a visual clinical report is generated, clinical executable operation is further strengthened, and through algorithm quantification, a dynamic knowledge graph, AI auxiliary decision making and a clinical operation closed loop, the next-generation technical research direction of a tumor precise drug use system can be represented.

The invention discloses an AIE type fluorescent probe with tumor targeting as well as preparation and application thereof, and belongs to the technical field of medicines, the probe can accurately target HDAC6 high-expression tumor cells, the specific binding capacity of the probe reduces interference to normal cells, and the detection accuracy is improved. The probe is fused with AIE performance dye molecules and emits strong fluorescence during aggregation, so that the imaging sensitivity and definition are remarkably enhanced. By optimizing the structure and synthesis conditions, the fluorescence intensity and stability of the probe are improved, the sensitivity of early tumor detection is ensured, and the survival rate and life quality of patients are improved. The preparation method is simple, convenient, feasible, low in cost and beneficial to practical application. The probe can be used for preparing tumor detection products, assisting in tumor diagnosis and classification, monitoring treatment changes and evaluating the curative effect. High-precision imaging can be realized in the aspect of tumor imaging, the method can be used for evaluating curative effect and guiding formulation of subsequent treatment schemes, and the application prospect is wide.

The invention discloses an enzyme response type KRAS targeted protein degradation chimera as well as a preparation method and application thereof, and belongs to the technical field of tumor targeted therapy. The enzyme response type KRAS targeted protein degradation chimera disclosed by the invention is obtained by covalently linking three parts, namely a KRAS targeted protein degradation chimera, an enzyme response type amino acid sequence and a cell penetrating peptide amino acid sequence, wherein the KRAS targeted protein degradation chimera is obtained by linking a KRAS targeted peptide and a VHL E3 ligase ligand through succinic acid. The enzyme response type KRAS targeted protein degradation chimera releases the KRAS targeted protein degradation chimera under the action of ATG4 enzyme shearing, and shows a relatively strong lung cancer resisting effect in vitro and in vivo. The invention has significant advantages in the aspect of antitumor drugs, and opens up a new field for the development of targeted protein degradation chimera drugs. Enzyme response type KRAS targeted protein degradation chimera molecular structural formula as follows: # imgabs0 #

The invention belongs to the field of biomedicine, and particularly relates to polypeptide for targeted blocking of combination of TRIM25 and BRD7 protein and application of the polypeptide. According to the present invention, based on the minimum binding region PRYSPRY structural domain (439 aa-630 aa) of the TRIM25 and the BRD7 protein, the blocking peptide TB16 capable of specifically blocking the mutual binding of the TRIM25 and the BRD7 protein is screened, such that the ubiquitination degradation of the BRD7 is inhibited, and the stability of the BRD7 tumor inhibition protein is improved. The polypeptide drug TB16 can effectively inhibit breast cancer, nasopharynx cancer, ovarian cancer, lung cancer and liver cancer cell proliferation and breast cancer in-vivo tumor growth, has good anti-solid tumor activity, and is expected to become a new anti-tumor targeting drug.

The present disclosure is a polyethylene glycol modified zwitterionic fluorescent probe. The core luminescent group of the fluorescent probe of the present disclosure is a heptamethine chain which is connected by a phenoxy bridge and has a rigid ring structure in the center. The two ends of the heptamethine chain are two sulfonic indole groups, and two polyethylene glycol chains are connected with the indole groups. A tumor targeting ligand is connected with a luminescent group through one polyethylene glycol chain and one alkaline amino acid spacer. The probe of the present disclosure can be connected with polypeptides, small molecules and antibodies having a tumor targeting function, thereby achieving near-infrared fluorescence imaging for tumor targeting. The probe of the present disclosure has good druggability, and is extremely suitable for industrial production and clinical promotion.

The invention provides a preparation method and application of a CD70 specific nano antibody molecular imaging probe. The probe comprises a tumor targeting group, radionuclide and a bifunctional chelating agent, the tumor targeting group is a CD70 specific nano antibody; the CD70 specific nano antibody is R8B4, and the amino acid sequence of the R8B4 is as shown in SEQ ID No. 1. The probe provided by the invention can realize noninvasive diagnosis of solid tumors such as renal clear cell carcinoma and malignant tumors of a blood system; reabsorption of the compound in the kidney is effectively inhibited through charge adjustment, kidney uptake is remarkably reduced, non-specific signals are reduced, the signal-to-noise ratio during targeted imaging or treatment is increased, and the imaging quality and treatment safety are improved. The probe not only has a wide application prospect in tumor diagnosis, but also provides a new technical support for targeted therapy and individualized precision medical treatment, and has important scientific research and clinical application values.

Disclosed in the present invention are an ecteinascidin compound and the use thereof. Provided in the present invention is a compound as represented by formula (I), or a pharmaceutically acceptable salt, an ester, a stereoisomer, a tautomer, a polymorph, a solvate, an isotopically labeled compound, a metabolite or a prodrug thereof. The compounds provided by the present invention have one or more effects selected from the following group: (1) having an inhibitory activity against tumor cell proliferation in vitro; (2) having a tumor inhibition effect in vivo; (3) having an in vivo tumor targeting capability; and (4) having good safety in vivo.

The invention provides a preparation method and application of a platelet-based targeting oncolytic virus delivery preparation, effective loading of oncolytic viruses is realized by infecting platelets with the oncolytic viruses, and meanwhile, the cellular structure of the platelets can be used as a physical barrier, so that the platelet-based targeting oncolytic virus delivery preparation is prepared. The tumor targeting drug delivery system shields the neutralizing and removing effects of in-vivo neutralizing antibodies / complements / removing cells on the oncolytic viruses, so that the oncolytic viruses can enter the body in a systematic drug delivery mode, tumor targeting drug delivery of the oncolytic viruses is achieved through the tumor targeting capacity of platelets, and the success of intravenous drug delivery and tumor targeting of the oncolytic viruses is achieved. The invention provides a technical support and a new idea for wider and more effective treatment of cancers, and has a good application prospect.

The invention discloses an AuAgPt ternary alloy nano-framework, a preparation method thereof and application of the AuAgPt ternary alloy nano-framework in anti-tumor preparations, and belongs to the field of biomedical nano-materials. The AuAgPt ternary alloy nano frame is a hollow octahedral nano frame formed by 12 AuAgPt ternary alloy edges, and the nano frame has plasmon photothermal conversion performance, catalase activity and peroxidase-like activity, and can be used for preparing the nano frame. The aptamer has the characteristics that the aptamer can form a covalent bond with glutathione (GSH), the aptamer with the framework surface capable of being modified and specifically bound with tumor cells is used for tumor targeted delivery and the like, the aptamer can be bound in a targeted manner and internalized into the tumor cells, and after near-infrared laser irradiation, the cell temperature can be increased to 42 DEG C, reactive oxygen species (ROS) can be generated, GSH can be consumed, and the tumor targeting effect is achieved. In addition, the content change of small molecule metabolites in cells can be driven through a low-temperature photothermal effect, the metabolic state is disturbed, the redox balance in the cells is destroyed, the tumor cells are induced to generate ferroptosis and apoptosis, and the low-temperature photothermal treatment of tumors is realized.

The invention discloses a tumor targeting reagent and application thereof in tumor diagnosis. The targeting reagent has strong affinity to tumors, strong specificity and no biotoxicity, is relatively stable in vivo, and can be used as a molecular probe to be applied to molecular imaging and / or treatment of various integrin alpha6 high-expression tumors; the targeting reagent provided by the invention comprises the tumor targeting peptide RWYDeA, and further comprises a radionuclide chelating agent, other connecting structures and a hydroxyl substitution structure, and the structure is beneficial to improving the tumor targeting property of the targeting reagent, prolonging the tumor binding time and achieving a better tumor diagnosis effect; the method can be used for preparing products for diagnosing / treating diseases related to high expression of integrin alpha6.

The invention discloses a polypeptide-based PROTAC condensation body as well as a preparation method and application of the polypeptide-based PROTAC condensation body. The polypeptide-based PROTAC aggregate comprises an HER2 (human epidermal growth factor receptor) targeting module, an EGFR (epidermal growth factor receptor) targeting module, a VHL E3 ligase targeting module and a self-assembly module. The polypeptide-based PROTAC condensation body can dynamically enrich E3 ligase VHL and promote efficient ubiquitination degradation of HER2, EGFR and downstream signal channel protein of HER2 and EGFR, the degradation efficiency of HER2 and EGFR protein can reach 92%, the degradation efficiency of downstream signal channel protein such as SOS2 and RAS can reach 80%, and in addition, the polypeptide-based PROTAC condensation body has the advantages that the polypeptide-based PROTAC condensation body can be used as an efficient ubiquitination condensation body; the polypeptide-based PROTAC condensation body has the characteristics of tumor targeting and long-acting retention, and dose-dependent tumor specific accumulation and retention can be realized through in-situ self-assembly.

The invention discloses a multifunctional nano-enzyme as well as a preparation method and application thereof, and belongs to the technical field of nano-enzyme synthesis. Aiming at the problems that a traditional nano-enzyme is single in activity, limited in treatment effect, poor in tumor active targeting specificity and the like, the multifunctional nano-enzyme provided by the invention is simple and efficient in preparation method, and is prepared by taking N and P double-doped hollow carbon nanospheres as a carrier, loading L-arginine and glucose oxidase and taking an aptamer as a targeting molecule. The multifunctional nano-enzyme is small in particle size, high in dispersion degree and good in biological safety. The multifunctional nano-enzyme not only has the activities of peroxidase, nitric oxide synthase and glucose oxidase, but also has excellent photo-thermal conversion capacity in tumor targeted therapy. The multifunctional nano-enzyme provided by the invention has a tumor focus specific recognition capability, can be highly enriched at a tumor part, finally realizes the purpose of photothermal / catalytic treatment combined tumor treatment, and provides a new thought and platform for tumor treatment.

The invention discloses a manganese-enriched albumin boron-containing nano preparation as well as a preparation method and application thereof, and belongs to the field of medicines and nano biological materials. According to the manganese-enriched albumin boron-containing nano preparation, albumin serves as a core carrier, phenylboronic acid derivatives are loaded through covalent or electrostatic interaction, then a manganese oxide layer is deposited on the surface in situ, and the prepared manganese-enriched albumin boron-containing nano preparation can remarkably increase the boron accumulation amount in tumor tissue; local and systemic immune response of tumors is promoted through the immune activation effect of manganese ions, so that the treatment effect of boron neutron capture therapy (BNCT) is remarkably improved. According to the invention, a phenylboronic acid derivative with tumor targeting is compounded with albumin, and manganese oxide is deposited in situ on the surface of the phenylboronic acid derivative, so that a multifunctional nano preparation with high boron delivery efficiency, immunological enhancement and magnetic resonance imaging functions is formed.

The invention discloses a dual-targeting macrophage membrane nano system and a preparation method and application thereof, and belongs to the field of biological medicine, MKA is wrapped in a macrophage membrane after AuNPs and mitochondrial targeting peptide KLA are connected. The preparation method comprises the following steps: firstly synthesizing AuNPs and modifying, and then wrapping with a macrophage membrane. In treatment, the compound can realize double targeting of tumor cells and mitochondria, enhance radiation-induced DNA damage, inhibit DDR, activate immune pathways and promote T cell infiltration, and can also consume glutathione and amplify oxidative stress to enhance immune effect, and the dose enhancement ratio of the compound in cooperation with 8GyX-rays reaches 3.1. In addition, the MKA is good in biocompatibility in vivo, long in blood circulation time, high in tumor targeting and capable of being quickly cleared through the kidney. The invention provides a new way for tumor radioimmunotherapy, and is helpful for promoting the progress of clinical tumor treatment.

The invention relates to a noninvasive solid tumor internal hypoxia condition detection method, which comprises: chemically modifying a near-infrared two-region fluorophore, an oxygen sensitive group and a tumor targeting group to construct a composite probe, collecting fluorescence and photoacoustic signals of a tumor region after intravenous injection, carrying out de-noising analysis, and combining with multiple parameters to solve hypoxia concentration change, a four-dimensional space-time distribution map is constructed by fusing vascular topological data, and individualized calibration is realized through microfluidic simulation and Bayesian optimization. Compared with a traditional invasive detection and single-mode imaging technology, the advantages of bimodal signals are integrated in a breakthrough mode, non-invasive, real-time and high-resolution dynamic hypoxia monitoring is achieved, acute and chronic hypoxia areas are accurately distinguished, tumor blood vessel heterogeneity interference is reduced through personalized parameter calibration, and the accuracy of hypoxia monitoring is improved. High-precision spatio-temporal data support based on hypoxia microenvironment monitoring is provided for solid tumor radiotherapy target planning, chemotherapy drug delivery optimization, chemotherapy drug resistance and curative effect prediction and evaluation and tumor metastasis progress risk analysis.

The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and / or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.

The invention relates to a Raman probe for detecting hydrogen sulfide as well as a preparation method and application of the Raman probe. The gold and silver nanocage (AuAg NCs) is prepared, and after the gold and silver nanocage (AuAg NCs) is modified by a Raman signal molecule 4-ethynylaniline (4EA), it is found that the AuAg-4EANCs shows the strongest Raman enhancement effect at the position of 2010 cm <-1 > located in a cell silence zone. The SERS probe with the tumor targeting capability is developed through the functional modification of a mucoprotein 1 aptamer (MUin1aptamer, MUC1Apt) and polyethylene glycol (PEG), and the SERS probe with the tumor targeting capability is further developed through the functional modification of the mucoprotein 1 aptamer (MUin1aptamer, MUC1Apt) and the PEG (Polyethylene Glycol). In the presence of hydrogen sulfide (H2S) and oxygen, Ag in AuAg-4EANCs rapidly reacts with H2S to generate Ag2S with significantly reduced Raman enhancement performance, resulting in sharp attenuation of 4EA signal intensity. And along with the increase of the H2S concentration, the generation amount of Ag2S is increased, so that a quantitative detection model dependent on the H2S concentration is established.

The invention provides a boron drug with tumor targeted release capability for boron neutron capture therapy and a preparation method thereof, relates to the technical field of tumor therapy, and provides a boron drug which can be activated through high-concentration NAD (P) H at a tumor site and can release a B-10 drug in a targeted manner for boron neutron capture therapy. A boron-10-containing compound in the boron medicine is connected with 3-aldehyde quinoline salt through a self-elimination reactive group, the 3-aldehyde quinoline salt can be specifically reduced by NAD (P) H rich in tumor cells to trigger chain reaction, and the effective boron-10 compound is released for boron neutron capture therapy. The damage to normal cells in the BNCT process can be effectively reduced by a method for targeted aggregation of the boron drug in the tumor cells. The boron drug synthesis method is simple, mild in condition and high in yield, has the advantages of stable chemical property, good light stability, small toxicity and the like, and provides a good application prospect for the field of boron neutron capture therapy.

The invention relates to the technical field of tumor fluorescence contrast agents, and particularly provides a conjugate of indocyanine green and multi-arm polyethylene glycol or pharmaceutically acceptable salt of the conjugate and a preparation method and application of the conjugate, the conjugate has the structural formula shown in the formula (I), the binding capacity of the conjugate and serum protein is remarkably reduced, and the conjugate can be applied to tumor fluorescence contrast agents. According to the present invention, the tumor targeting property is significantly improved, and the tumor is accumulated and detained in the tumor tissue, such that the targeted treatment or the high-resolution imaging is achieved so as to achieve the accurate tumor positioning and diagnosis, the high application value is provided, and the new method is developed for the tumor imaging and the treatment.

The invention belongs to the technical field of biological medicines, and discloses a VEGFR-2 affinity peptide and application thereof, the VEGFR-2 affinity peptide can target a vascular endothelial growth factor receptor VEGFR-2, so that the VEGFR-2 affinity peptide can carry out in-vivo diagnosis on tumors with high expression of the VEGFR-2 receptor, and therefore, the VEGFR-2 affinity peptide can be used for in-vivo diagnosis of tumors with high expression of the VEGFR-2 receptor. The VEGFR-2 affinity peptide provided by the invention can be applied to preparation of a novel tumor diagnostic reagent or a novel tumor targeted drug carrier.

The invention relates to an HER2 (human epidermal growth factor receptor 2) targeting antibody coupling gold (III) porphyrin medicine as well as a synthesis method and tumor treatment application thereof. The antibody coupling gold (III) porphyrin drug targeting HER2 is formed by connecting an anti-HER-2 trastuzumab and an A3B type gold (III) porphyrin complex through a linker, and the linker comprises a maleimide joint connected with an antibody and a self-elimination joint connected with the A3B type gold (III) porphyrin complex. The A3B type gold (III) porphyrin complex with anti-tumor activity is combined with trastuzumab with a specific recognition function as a carrier, the antibody is utilized to accurately strike tumor cells, a medicine is delivered to a tumor environment, the tumor targeting property of the gold (III) porphyrin complex is improved, and accurate treatment is realized. Distribution of drugs in the body can be improved, accumulation of the drugs in non-tumor sites can be reduced, the dosage of metal complexes is reduced, and toxic and side effects are reduced; the efficient delivery of gold drugs to tumor tissues can also be realized, and the cancer treatment effect is improved.

The invention discloses preparation and anti-tumor application of tumor cell membrane coated Ilisimus / copper-NLG919 bionic nanoparticles, and particularly relates to a bionic nano-drug which is characterized in that NLG919, ES and Cu < 2 + > are used as active ingredients to construct a self-assembled drug system (ECN), and meanwhile, a tumor cell membrane is used for coating the ECN to form ECNM; compared with a traditional EC, the built ECNM has the advantages that the systemic circulation stability, tumor targeting and tumor accumulation of the EC are remarkably improved, copper death and chemical kinetic therapy (CDT) can be efficiently triggered, a tumor immunosuppression microenvironment (TIM) can be synergistically reversed, and then a higher tumor immunotherapy effect is achieved. The nano-drug disclosed by the invention has good biological safety, cycling stability and homologous tumor targeting property, the preparation method is simple and convenient, and materials and equipment are easy to obtain.

The invention discloses a chimera for targeted degradation of GPX4 based on HSP70 protein as well as a preparation method and application of the chimera, and belongs to the technical field of biological medicines. According to the invention, 12 chimeras for targeted degradation of GPX4 are prepared by using the technology. The HSP70 molecular chaperone complex mediated protein targeted degradation chimera provided by the invention can rapidly and durably induce the degradation of GPX4. Meanwhile, the chimeras have obvious anti-proliferative activity on GPX4 high-expression cell strains and high-selectivity induction of ferroptosis of cells, and have important significance on tumor targeted therapy and drug resistance overcoming.

The invention relates to an immune sensitization IRE treatment platform based on NK cell membrane coated manganese carbonate. A manganese carbonate composite nano material is formed by coating the surfaces of manganese carbonate nano particles with cell membranes. According to the invention, higher tumor specificity enrichment is realized, non-target tissue accumulation and systemic toxicity risks are reduced, collaborative integration of tumor targeted delivery, immune activation and IRE ablation is realized, and compared with single IRE, anti-tumor immune response is significantly enhanced.

The invention discloses a multifunctional tumor targeted low-temperature treatment nano platform and application thereof, and belongs to the technical field of nano biological medicines. According to the multifunctional tumor targeted low-temperature treatment nano platform, the two-dimensional Ti3C2 nano material serves as a carrier, indocyanine green is loaded to serve as a photosensitizer, polydopamine is modified on the surface to improve the stability, and gambogic acid is loaded to serve as an anti-tumor drug and a heat shock protein inhibitor; and a nucleic acid aptamer capable of recognizing specific protein on the cell surface is coupled in a covalent binding manner. The multifunctional tumor targeted low-temperature treatment nano platform is small in particle size, high in dispersion degree and good in biocompatibility, and shows excellent photo-thermal conversion capacity, photodynamic treatment effect and chemotherapy effect in tumor targeted treatment. The apoptosis of tumor cells can be effectively induced under a relatively low temperature condition, and the damage of high temperature to surrounding healthy tissues is remarkably reduced. The tumor focus specific recognition capability is also realized, the high enrichment at the tumor part can be realized, and the treatment effect is enhanced.

The invention discloses a chimera for targeted degradation of immune protein. The chimera is formed by connecting a ligand of E3 ligase with a ligand of IDO protein through a linker. The invention also discloses a preparation method and application thereof. According to the present invention, a ligand capable of degrading immune-related protein-indoleamine 2, 3-dioxygenase (IDO) is coupled with a ligand of E3 ligase through a linker to construct the PROTAC capable of being used for tumor immunotherapy; the molecule can specifically degrade indoleamine 2, 3-dioxygenase, so that the effects of tumor targeting and immunotherapy are achieved, and the maximum killing effect on tumor cells and tissues is achieved.

The invention provides application of an ENO1K71R mutant as a target spot in screening preparations for regulating and controlling glycolysis of colon cancer cells and improving tumor microenvironment, and belongs to the technical field of biological medicine and molecular biology. The research on the colon cancer cells which stably knock down PCSK9 finds that PCSK9 achieves the regulation effect on lactic acid metabolism in the colon cancer cells by regulating ENO1 lactic acid modification, the blank of ENO1 protein lactic acid modification and the regulation effect of the ENO1 protein lactic acid modification in tumor progression is filled, a lactic acid modification site is verified by constructing an ENO1K71R mutation experience, and the result shows that the PCSK9 can be used for regulating the lactic acid metabolism in the colon cancer cells. After ENO1 (K71) point mutation, ENO1 lactic acid can be inhibited, a new site is provided for ENO1 lactic acid modification, and a theoretical basis is also provided for developing novel tumor targeted drugs.

The invention belongs to the technical field of biochemistry, and relates to a ratio type photoacoustic probe responding to nitrosyl peroxide as well as a preparation method and application of the ratio type photoacoustic probe. The structural formula of the probe is as follows: # imgabs0 #. The ratio type photoacoustic probe provided by the invention has high selectivity and sensitivity; after response with ONOO <->, the absorption wavelength red shift of the formed hydroxyl negative ions is about 100 nm, and the characteristic of obvious ratio-type response is achieved; the stability is good under the physiological pH condition, and real-time in-situ imaging of ONOO <-> is facilitated; the probe itself has a strong photoacoustic signal. According to the preparation method of the ratio type photoacoustic probe, the adopted raw materials are easy to obtain, the reaction conditions are mild and easy to control, the reaction cost is saved, and the yield of a target product is guaranteed. The ratio type photoacoustic probe BXos4 provided by the invention has efficient tumor targeting ability, provides a new detection means for detection of ONOO <->, and provides a potential tool for diagnosis of tumors.

The invention discloses iron oxide nanoparticles capable of responding to particle size change in a tumor microenvironment and a preparation method of the iron oxide nanoparticles, and belongs to the technical field of biomedical nano materials. The nano-particle comprises an iron oxide nano-crystal core with the particle size of 3-5nm and a tumor microenvironment response layer coating the surface of the iron oxide nano-crystal core. The response layer contains groups, such as disulfide bonds, enzyme digestion peptide fragments and the like, which can respond to acidic pH, high-concentration reduced glutathione or matrix metalloproteinase and other tumor characteristic stimuli to generate structural changes. In a tumor microenvironment, the hydration particle size of the nanoparticles can be directionally and controllably converted from 3-20 nm to 20-100 nm (or reversely). The preparation method mainly comprises two steps of preparing the core by a thermal decomposition method and modifying the surface response layer. The technical problems of insufficient tumor targeted enrichment capacity, limited imaging contrast and difficulty in balancing permeation and retention caused by fixed particle size of the existing iron oxide nanoparticles are solved, and the accuracy and efficiency of tumor diagnosis and treatment can be remarkably improved.

The invention belongs to the technical field of biomedical functional dyes and probes, and relates to a fluorescent probe, in particular to a cyclodextrin-based near-infrared fluorescent probe, which is a conjugate formed by coating a fluorescent molecule with cyclodextrin. According to the near-infrared fluorescent probe disclosed by the invention, cyclodextrin is nested on a carbon chain of a fluorescent molecule, so that the water solubility, histocompatibility and safety are improved, the fluorescence lifetime is prolonged, the light stability is improved, and rapid transmission and response of ureters, lymphatic vessels and lymph nodes in vivo are realized; the method can be used for NIR-I and NIR-II imaging; a near-infrared fluorescence probe with targeting property can be formed by marking various tumor targeting molecules, so that accurate targeting fluorescence imaging of different types of tumors such as urogenital tumors, head and neck cancers, breast cancers and cervical cancers and metastatic lymph nodes in NIR-I and NIR-II windows is realized, and the near-infrared fluorescence probe can be applied to fluorescence imaging navigation in clinical operations.